Clinical Trial Update: Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND) [Phase 3]

View source ↗

Summary

This update reports results from the Phase 3 EXPAND trial evaluating siponimod for secondary progressive multiple sclerosis, including assessments of efficacy a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Multiple Sclerosis

Drugs mentioned

• MAYZENT (siponimod)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Secondary Progressive Multiple Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2018-10-31